Last reviewed · How we verify
NCT02385214: MelMarT
MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
NA trial testing Wide Local Excision = 1cm Margin in Cutaneous Melanoma by AJCC V7 Stage in 400 participants. Participants enrolled and being followed up; not accepting new ones.
4 August 2016
Quick facts
| Lead sponsor | Melanoma and Skin Cancer Trials Limited |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 400 |
| Start date | 3 January 2015 |
| Primary completion | 4 August 2016 |
| Estimated completion | 5 August 2026 |
| Sites | 20 locations across Sweden, United Kingdom, Canada, Australia, United States |
Drugs / interventions tested
- Wide Local Excision = 1cm Margin
- Wide Local Excision = 2cm Margin
Conditions studied
- Cutaneous Melanoma by AJCC V7 Stage — all drugs for Cutaneous Melanoma by AJCC V7 Stage →
Sponsor
Melanoma and Skin Cancer Trials Limited — full company profile →
Who can join
18 and older, any sex, with Cutaneous Melanoma by AJCC V7 Stage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas \>=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial.
Hayes AJ, Maynard L, Coombes G, Newton-Bishop J, et al · · 2016 · cited 88× · PMID 26790922 · DOI 10.1016/s1470-2045(15)00482-9 -
1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study.
Moncrieff MD, Gyorki D, Saw R, Spillane AJ, et al · · 2018 · cited 37× · PMID 29850955 · DOI 10.1245/s10434-018-6470-1 -
A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management.
Orme SE, Moncrieff MD. · · 2024 · cited 11× · PMID 38473257 · DOI 10.3390/cancers16050895 -
The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.
Nacchiero E, Giotta M, Robusto F, Metta ME, et al · · 2024 · cited 1× · PMID 39321036 · DOI 10.1097/cmr.0000000000000999 -
Variation in the Surgical Care of Early Stage Melanoma Based on Surgical Subspecialty: Evaluation of Large Healthcare System.
Lourdault K, Cowman AW, Reyes E, Lascano D, et al · · 2026 · PMID 41890515 · DOI 10.1097/as9.0000000000000650
Verify or expand the search:
- PubMed search for NCT02385214
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Wide Local Excision = 1cm Margin
Trials testing the same drug.
- NCT03860883 — Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma · NA · recruiting
Other recruiting trials for Cutaneous Melanoma by AJCC V7 Stage
Currently open trials in the same condition.
- NCT07148245 — Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma · recruiting
Other Melanoma and Skin Cancer Trials Limited trials
Trials by the same sponsor.
- NCT06418724 — Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06163820 — Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases · Phase 1, PHASE2 · recruiting
- NCT05860881 — Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) · Phase 3 · active not recruiting
- NCT04291885 — Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma · Phase 2 · active not recruiting
- NCT03860883 — Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02385214 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Melanoma and Skin Cancer Trials Limited
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02385214.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing